Background and Objectives: It has been suggested that inflammatory cytokines such as Interleukin (IL)–1β, IL–6, tumor necrosis factor–α (TNF–α) and IL–8 might be responsible for a large number of non–antibody–mediated adverse reactions to the transfusion of blood components, especially of platelet concentrates (PCs). The aim of this study was to compare the levels of proinflammatory cytokines in different blood components containing red cells such as buffy–coat–free packed red cells (RBCs), filtered RBCs and whole blood (WB) during storage under several conditions. Materials and Methods: WB (CPD–A1, n = 16) was stored for 35 days at 2–6°C; samples were taken on days 0, 21 and 35. Buffy–coat–poor RBCs in additive solution PAGGS–M (n = 16) were divided into halves, one half was leukocyte (WBC)–depleted by filtration on day 0, both halves were stored for 49 days at 2–6°C (samples: days 0, 21, 49). Furthermore, buffy–coat–poor, unfiltered SAG–M RBCs (n = 16) were halved immediately after production and stored at 2–6°C until day 42 (samples: days 0, 21, 42). One half remained at room temperature for 24 h on day 3. Cytokine levels were determined with commercial enzyme–linked immunosorbent assays. Results: Levels of IL–1β and TNF–α rose during storage of WB and RBCs. IL–6 could be detected markedly above the detection threshold in WB only. At the end of storage, we detected IL–8 in 1 of 16 units of WB tested, in 10 of 16 standard PAGGS–M RBCs and in 15 of 16 temporarily warmed SAG–M RBCs. Prestorage filtration of RBCs prevented the accumulation of IL–1β and TNF–α. Temporarily warming of RBCs for 24 h did not cause any substantial increase in cytokine levels other than IL–8. RBCs stored in different additive solutions (PAGGS–M versus SAG–M) showed similar cytokine concentrations during storage. The cytokine content of WB was very similar to that of buffy–coat–poor RBCs. Conclusion: Cytokine levels measured in WB and buffy–coat–poor RBCs result in levels which are unlikely to cause febrile reactions even in the case of massive transfusion. We conclude that, according to present knowledge, there is no reason for prestorage filtration of buffy–coat–poor RBCs or WB to avoid febrile transfusion reactions due to cytokine accumulation during storage.

1.
Chambers LA, Kruskall MS, Pacini DG, Donovan LM: Febrile reactions after platelet transfusion: The effect of single versus multiple donors. Transfusion 1990;30:219–221.
2.
Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG: A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993;33:794–797.
3.
Klüter H, Müller–Steinhardt M, Wilhelm D, Kirchner H: Cytokines in platelet concentrates prepared from pooled buffy coats. Vox Sang 1995;69:38–43.
4.
Flegel WA, Wiesneth M, Stampe D, Koerner K: Low cytokine contamination in buffy coat–derived platelet concentrates without filtration. Transfusion 1995;35:917–920.
5.
Oksanen K, Ebeling F, Kekomäki R, Elonen E, Sahlstedt L, Volin L, Myllylä G: Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 1994;67:356–361.
6.
Muylle L, Wouters E, De Bock R, Peetermans ME: Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfus Med 1992;2:289–293.
7.
Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME: Increased tumor necrosis factor–α (TNF–α), interleukin 1, and interleukin 6 (IL–6) levels in the plasma of stored platelet concentrates: relationship between TNF–α and IL–6 levels and febrile transfusion reactions. Transfusion 1993;33:195–199.
8.
Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walker I, Kelton JG: The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625– 628.
9.
Muylle L, Wouters E, Peetermans ME: Febrile reactions to platelet transfusion: The effect of increased interleukin 6 levels in concentrates prepared by the platelet–rich plasma method. Transfusion 1996;36:886–890.
10.
Ferrara JLM: The febrile platelet transfusion reaction: A cytokine shower (editorial). Transfusion 1995;35:89–90.
11.
Aye MT, Palmer DS, Giulivi A, Hashemi S: Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1994; 35:117–124.
12.
Sweeney JD, Holme S, Stromberg RR, Heaton WAL: In vitro and in vivo effects of prestorage filtration of apheresis platelets. Transfusion 1995;35:125–130.
13.
Muylle L, Peetermans ME: Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66:14–17.
14.
Wadhwa M, Seghatchian MJ, Lubenko A, Contreras M, Dilger P, Bird C, Thorpe R: Cytokine levels in platelet concentrates: Quantitation by bioassays and immunoassays. Br J Haematol 1996;93:225–234.
15.
Davenport RD, Kunkel SL: Cytokine roles in hemolytic and nonhemolytic transfusion reactions. Transfus Med Rev 1994;VIII:157–168.
16.
Stack G, Snyder EL: Cytokine generation in stored platelet concentrates. Transfusion 1994;34:20–25.
17.
Stack G, Baril L, Napychank P, Snyder EL: Cytokine generation in stored, white cell reduced, and bacterially contaminated units of red cells. Transfusion 1995;35:199–203.
18.
Kristiansson M, Soop M, Saraste L, Sundqvist KG: Cytokines in stored red blood cell concentrates; promoters of systemic inflammation and simulators of acute transfusion reactions? Acta Anaesthesiol Scand 1996;40:496–501.
19.
von Eisenhart–Rothe B: Vollblut oder Blutkomponenten bei Eigenblut vor planbaren Operationen; in Mempel W, Schwarzfischer G, Mempel CH (eds): Eigenbluttransfusion heute. München, Sympomed, 1995, pp 64–69.
20.
Richtlinien zur Blutgruppenbestimmung und Bluttransfusion. Köln, Deutscher Ärzte–Verlag, 1992.
21.
Guide to the Preparation, Use and Quality Assurance of Blood Components. Strasbourg, Council of Europe Press, 1992.
22.
Zwart A, Buursma A, van Kampen EJ, Oeseburg B, van der Ploeg PH, Zijlstra WG: A multi–wavelength spectrophotometric method for the simultaneous determination of five haemoglobin derivatives. J Clin Chem Clin Biochem 1981;19:457–463.
23.
Darbonne WC, Rice GC, Mohler MA, Apple T, Hebert CA, Valente AJ, Baker JB: Red blood cells are a sink for interleukin 8, a leucocyte chemotaxin. J Clin Invest 1991;88:1362– 1369.
24.
Van Zee KJ, Fischer E, Hawes AS, Hebert CA, Terrell TG, Baker JB, Lowry SF, Moldawer LL: Effects of intravenous IL–8 administration in nonhuman primates. J Immunol 1992;148: 1746–1752.
25.
Rot A: Some aspects of NAP–1 pathophysiology: Lung–damage caused by a blood–borne cytokine. Adv Exp Med Biol 1991;88:1362– 1369.
26.
Tewari A, Buhles WC, Starnes HF: Preliminary report: Effect of interleukin–1 on platelet counts. Lancet 1990;336:712–714.
27.
Dinarello CA: Interleukin–1 and interleukin–1 antagonism. Blood 1991;77:1627–1652.
28.
Blick MB, Sherwin SA, Rosenblum MG, Gutterman JU: A phase I trial of recombinant tumor necrosis factor (rTNF) in cancer patients (abstract). Proc Am Soc Clin Oncol 1986;5:14.
29.
Ledent E, Berlin G: Inadequate white cell reduction by bedside filtration of red cell concentrates. Transfusion 1994;34:765–768.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.